Navigation Links
Ondine Biopharma CEO Nominated for Manning Innovation Award
Date:6/2/2010

Carolyn Cross, Chairman and CEO of Ondine Biopharma, has been selected as a nominee for a 2010 Manning Innovation Award. Ms. Cross, together with 5 other nominees from across British Columbia, were recently honoured at the Parliament Buildings in Victoria by being introduced to the Legislature by Minister Moira Stilwell. Ms. Cross was nominated for this prestigious award in connection with her support of the development of Photodisinfection, an innovative non-antibiotic antimicrobial technology, and her efforts behind Ondine Biopharma Corporation, a globally recognized leader in developing and commercializing this innovative platform technology.

Vancouver, BC (PRWEB) June 2, 2010 -- Ondine Biopharma Corporation (the "Company" or "Ondine", TSX: OBP; AIM:OBP) is pleased to announce that Carolyn Cross, Chairman and CEO of Ondine, has been selected as a nominee for a 2010 Manning Innovation Award. Ms. Cross, together with 5 other nominees from across British Columbia, were recently honoured at the Parliament Buildings in Victoria by being introduced to the Legislature by Minister Moira Stilwell.

Ms. Cross was nominated for this prestigious award in connection with her support of the development of Photodisinfection, an innovative non-antibiotic antimicrobial technology, and her efforts behind Ondine Biopharma Corporation, a globally recognized leader in developing and commercializing this innovative platform technology. Photodisinfection is a two-step process involving non-thermal light energy to safely destroy bacteria, fungi and virus without contributing to antibiotic resistance. Photodisinfection for oral applications was invented by Professor Michael Wilson of University College London in the 1980's. The first product developed by Ondine using Photodisinfection, Periowave™, was successfully launched into the Canadian and European dental markets for the treatment of periodontal disease, a widespread disorder associated with increased risk of stroke, diabetes, heart disease, cancer and pre-term births. Periowave™ has been submitted to the US-FDA for pre-market review and approval. Ondine is currently working on Photodisinfection applications for treatment of chronic sinusitis, ventilator-associated pneumonia, and MRSA decolonization where the non-antibiotic alternatives are limited and the costs to patients, hospitals and the healthcare system are high.

"This recognition is a great endorsement of both the importance of Photodisinfection and of the dedicated and talented Ondine team," said Ms. Cross, "We launched Photodisinfection in the dental market, and we are now demonstrating its potential to prevent and treat infections (including those caused by antibiotic-resistant superbugs) that are otherwise untreatable. Ondine is committed to developing revolutionary Photodisinfection therapies that will save lives, and we are excited to introduce these treatments into patient populations that so desperately need them. Over 8,000 Canadians are succumbing annually to hospital acquired infections (HAI), and many of these deaths are associated with antibiotic resistant bacteria. In addition, Photodisinfection works well against viral organisms, where no antibiotic is of any use. I sincerely appreciate the Manning Award nomination, and want to thank the Foundation for their recognition of Photodisinfection as an important and worthy innovation."

The Ernest C. Manning Awards, named in honour of a great Canadian statesman, are widely recognized as the premier innovation awards in Canada. The Manning Awards Foundation has been recognizing and encouraging innovation in Canada since 1982. By means of a nomination, Canadians who have demonstrated recent innovative talent in developing and successfully marketing a new concept, process or procedure, may be eligible for one of four awards.

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratory in Bothell, Washington, USA.

For additional information, please visit the Company's website at: www.ondinebiopharma.com.

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's public filings.

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For further information please contact:

Carolyn Cross, Chairman and CEO
Ondine Biopharma Corporation

Canaccord Genuity Limited, Nominated Adviser
Ryan Gaffney
+4420 7050 6500

###

Read the full story at http://www.prweb.com/releases/CarolynCross/OndineBiopharma/prweb4083634.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Therapure Biopharma Inc. signs fill/finish contract with Kane Biotech Inc.
2. Therapure Biopharma Inc. signs multi-year manufacturing agreement with LFB Biomedicaments
3. PDL BioPharma Announces Two $0.50 Dividends in 2010
4. Therapure Biopharma Inc. Commissions its Commercial-Scale Lyophilizer
5. Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry
6. Seven More Biopharmaceutical Research Companies Join PhRMA
7. BioProcess International Launches a New and Improved Website for Biopharmaceutical Managers and Scientists
8. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
9. Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
10. Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009
11. CelebrityDiagnosis.com Nominated as Best New Medical Blog of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Ondine Biopharma CEO Nominated for Manning Innovation Award 
(Date:2/5/2016)... ... , ... The event is being held on April 7, 2016 from 5:30 ... Over Parkinson’s will fund nearly $100,000 for research for the care and cure of ... and is the architect of this informative event to raise awareness and funds for ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe ... signed a joint enrollment and degree completion agreement. The agreement, which begins ... degrees at FHU|Dickson. , The agreement allows students to be jointly admitted ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchises from across the country gathered at the La Valencia Hotel in San ... PROSHRED Chicago was named the year’s most outstanding franchise, walking away with ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one ... time for this weekend’s Big Game. Take the stress out of your party preparation ... your guests happy at every stage of the game. , “The key to hosting ...
(Date:2/5/2016)... ... February 05, 2016 , ... Stuart Bentkover, MD, FACS is ... to provide the most effective tattoo removal today, Dr. Bentkover is the only doctor ... by Cynosure, the PicoSure has been approved by the Food and Drug Administration (FDA) ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... 4, 2016  Omnicell, Inc. (NASDAQ: OMCL ), a ... healthcare systems, today announced results for its fiscal year ... --> --> GAAP results: Revenue for ... $5.1 million or 4.1% from the third quarter of ... fourth quarter of 2014. Revenue for the year ended ...
(Date:2/4/2016)... Feb. 4, 2016 In response to the opioid ... Deputy Commissioner for Medical Products and Tobacco, along with other ... the agency,s approach to opioid medications. The plan will focus ... patients in pain access to effective relief. ... , Re-examine the risk-benefit paradigm for opioids and ensure ...
(Date:2/4/2016)... -- --> --> ... Automated External Defibrillator (AED) Market by Product (Semi-Automated External ... Hospitals, Homecare & Nursing Homes) - Forecast to 2019", ... and segments the concerned market with an analysis and ... grow to about $367.0 million by 2019, at a ...
Breaking Medicine Technology: